|
| Shenqi Fuzheng Injection (参芪扶正注射液) for Advanced Gastric Cancer: A Systematic Review of Randomized Controlled Trials |
| |
| View Full Text View/Add Comment Download reader |
|
| KeyWord:chemotherapy, Shenqi Fuzheng Injection, advanced gastric cancer, Chinese medicine, systematic review, randomized controlled trial |
| Author Name | Affiliation | E-mail | | LI Jiang, WANG Jian-cheng, MA Bin | | | | YANG Ke-hu | 1. Evidence-Based Medicine Center, College of Basic Medicine, Lanzhou University, Lanzhou (730000), China
2. Institute of Integrated Traditional Chinese and Western Medicine, College of Basic Medicine, Lanzhou University, Lanzhou (730000), China
3. Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province, Lanzhou (730000), China | kehuyangebm2006@126.com |
|
| Hits: 866 |
| Download times: 87 |
| Abstract: |
| Objective: To evaluate the effectiveness of Shenqi Fuzheng Injection (参芪扶正注射液, SFI) combined with chemotherapy for advanced gastric cancer. Methods: Randomized controlled trials (RCTs) from 10 databases were searched for this meta-analysis till December 31, 2012 without language restriction. Grey literature and potential unpublished literature was also searched. The key search terms were "chemotherapy", "Shenqi Fuzheng Injection" and "advanced gastric cancer". Criteria were built to select these clinical trials, in which SFI combined with chemotherapy was compared with chemotherapy alone for advanced gastric cancer. The methodological quality of each RCT was assessed using the Cochrane risk of bias tool. RevMan 5.1 software was applied for data analyses. Results: Thirteen RCTs involving 860 patients met the selection criteria (all articles were from Chinese databases). The meta-analysis showed positive results for the use of SFI combined with chemotherapy according to quality of life in terms of the scores when compared with chemotherapy alone. Positive results were also obtained for the combination treatment, in terms of complete remission and partial remission efficacy rate, body weight and decreased adverse events including nausea and vomiting at grade 3–4, oral mucositis at grade 1–2, leucopenia at grade 3–4, and myelo-suppression at grade 1–2. Conclusions: This systematic review found encouraging albeit limited evidence for SFI combined with chemotherapy. However, to obtain stronger evidence without the drawbacks of trial design and the quality of studies, we recommend comparative effectiveness researches to test the effectiveness of combination treatment. |
| Close |
|
|
|
